Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sarilumab in adults hospitalized with COVID-19 and cytokine release syndrome
2020-001531-27Phase 2Completed
- Sponsor
- Fundación para la Investigación Biomédica de Córdoba
- Start
- Apr 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2 trial of sarilumab in coronavirus disease 2019 (COVID-19) and cytokine release syndrome (CRS), sponsored by Fundación para la Investigación Biomédica de Córdoba. Primary endpoint: Need for advanced respiratory support. Started Apr 2020; status: completed.
02
Drugs
sarilumab
03
Conditions
coronavirus disease 2019 (COVID-19)cytokine release syndrome (CRS)
Beyond the preview
Go deeper on 2020-001531-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001531-27.